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Abstract 
Background: Because the relationship between C-peptide and diabetic peripheral neuropathy (DPN) is controver-
sial, the aim of our study was to evaluate the relationship between C-peptide and DPN in community-based Chinese 
patients with type 2 diabetes.
Methods: In total, 220 consecutive type 2 diabetic patients treated by our regional medical consortium were 
enrolled. DPN was assessed by clinical symptoms, signs, and electromyography.
Results: Fasting C-peptide, 2-h postprandial C-peptide and ΔC-peptide (i.e., 2-h postprandial C-peptide minus the 
fasting C-peptide) serum concentrations in the non-DPN group were significantly higher than those in the clinical 
DPN group (all P ≤ 0.040) and the confirmed DPN group (all P < 0.002). The three C-peptide parameters were inde-
pendently associated with DPN (all P < 0.05) after adjusting for age, sex, diabetes duration, smoking status, systolic 
pressure, body mass index, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker use, fasting 
plasma glucose, HbA1c, triglyceride and estimated glomerular filtration rate. Compared with the ΔC-peptide quartile 
1 (reference), patients in quartile 3 (odds ratio [OR], 0.110; 95% confidence interval [CI] 0.026–0.466; P = 0.003) and 
quartile 4 (OR, 0.012; 95% CI 0.026–0.559; P = 0.007) had a lower risk of DPN after adjusting for the confounders.
Conclusions: C-peptide was negatively associated with DPN in community-based Chinese type 2 diabetic patients 
in China.
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Background
Diabetic peripheral neuropathy (DPN) is a well-known 
microvascular complication of type 2 diabetes mellitus, 
which leads to further infections and increases the risk 
of foot ulcers, non-traumatic amputations and mortality 
[1, 2]. Although hyperglycemia plays an important role 
in the development of DPN, intensive glucose control 
does not eliminate the risk of developing DPN in patients 
with type 2 diabetes, suggesting that other factors may be 
involved in DPN development [3].
C-peptide levels in the peripheral blood are widely 
accepted as the most appropriate evaluation of insulin 
secretion, and are not eliminated in the first-pass metab-
olism through the liver [4, 5]. Previously considered to be 
an inactive by-product of insulin synthesis, C-peptide is 
a hormonally active peptide [5, 6]. In type 1 diabetes, an 
Italian study with a large clinical cohort demonstrated a 
significant association between C-peptide and micro-
vascular complications, including neuropathy [7]. Sev-
eral studies in animal models of diabetes and in patients 
with type 1 diabetes have demonstrated beneficial effects 
of C-peptide replacement on both peripheral and auto-
nomic nerve function in diabetes [8–10].
In contrast to the data collected in patients with type 1 
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and in type 2 diabetes mellitus-related complications 
were conflicting. Whereas some studies showed that 
residual insulin secretion, evaluated by serum C-peptide 
concentrations, has a protective effect on diabetic neu-
ropathy [11–13], others either did not find such an effect 
[14], or concluded a contrary relationship [15]. Moreover, 
none of the studies focused on a community-based popu-
lation [13]. Therefore, the aim of this study was to evalu-
ate the relationship between C-peptide levels and DPN, 
independent of glycemic control and other risk factors in 
community-based Chinese type 2 diabetic patients.
Methods
Subjects
In total, 220 consecutive type 2 diabetic patients receiv-
ing care from the Jing’an regional medical consortium 
with completed demographic information and neurologi-
cal examination were enrolled in this study. World Health 
Organization diagnostic criteria were used for type 2 
diabetes diagnoses [16]. Patients with acute complica-
tions of diabetes, renal dysfunction (estimated glomeru-
lar filtration rate [eGFR]  <60  mL/min/1.73  m2), acute 
cerebral infarction, vitamin B12 deficiency, alcohol abuse 
and asymmetrical neuropathy of the trunk or proximal 
lower limbs and chronic infection were excluded from 
this study. All the patients signed the consent form for 
allowing their information to be used for research. The 
study was approved by the Ethics committee of Huashan 
Hospital, Fudan University and all patients provided 
informed consent.
Anthropometric measurements
Body weight was assessed with the patients wearing light 
clothing and no footwear before breakfast; all heights 
measurements were taken using the same wall-mounted 
stadiometer. Body mass index (BMI) was calculated as 
body weight (in kg) divided by the square of the height 
(in m). Diastolic blood pressure (DBP) and systolic blood 
pressure (SBP) were measured three times with 1-min 
intervals after 10 min of using a standard mercury sphyg-
momanometer and then averaged.
Laboratory measurements
Glucose and C-peptide concentrations were measured 
at baseline and 2  h following oral administration of a 
100-g steamed bread meal test (equal to 75 g of glucose). 
ΔC-peptide levels were calculated as the 2-h postpran-
dial serum C-peptide level minus the fasting C-peptide 
level. Although not a standard test in diabetes research 
or care, the 100 g steamed bread meal test was selected 
because it avoids severe glucose fluctuation in patients 
with type 2 diabetes mellitus [17]. Fasting blood samples 
were collected in a sodium fluoride anticoagulant tube, 
an EDTA anticoagulant tube and a coagulating tube. 
Glucose, glycosylated hemoglobin A1c (HbA1c) and bio-
chemical indicators including serum creatinine (Cr), and 
lipid profiles including total cholesterol (TC), triglyceride 
(TG), high-density lipoprotein-cholesterol (HDL-C) and 
low-density lipoprotein-cholesterol (LDL-C) were meas-
ured. 2-h postprandial blood samples were also collected 
for glucose and C-peptide measurements. Fasting plasma 
glucose (FPG) and 2-h postprandial plasma glucose 
(2 h-PG) concentration was estimated using the hexoki-
nase method (Wako pure 2756-01, Wako Pure Chemi-
cal Industries, Osaka, Japan) and an automatic analyzer 
(Hitachi 7600-120, Hitachi High-Technologies, Schaum-
burg, America). Whole blood was used to measure 
HbA1c by high-pressure liquid chromatography using 
an analyzer (HLC-723G7, Tosoh Corporation, Tokyo, 
Japan) and the matched calibrators and controls in a sam-
pling volume of 200 μL. For measurements of biochemi-
cal indicators, blood was centrifuged at 3000  r/min for 
10  min within 30  min of collection (5810R, Eppendorf, 
Hamburg, Germany) and the serum was collected for 
subsequent testing. Serum TC (GPO-DAOS method, 
Wako Pure Chemical Industries), TG (DAOS method, 
Wako Pure Chemical Industries), HDL-C (Direct 
method, Sekisui Medical Technology, Shanghai, China), 
and LDL-C (Direct method, Sekisui Medical Technol-
ogy, Osaka, Japan) of all the patients were estimated on 
the analyzer (Hitachi 7600-120). Glycated albumin (GA) 
was measured by an enzymatic assay (Lucica GA-L, 
Asahi Kasei Corporation, Tokyo, Japan) on the automatic 
analyzer (Hitachi 7600-120) using a sample volume of 
10  μL. C-peptide was measured by chemiluminescence 
(Siemens Healthcare Diagnostics, Malvern, USA) on an 
ADVIA Centaur XP automatic analyzer (Siemens Health-
care Diagnostics) using a sample volume of 200 μL. The 
glomerular filtration rate (GFR) was estimated using the 
modification of diet in renal disease (MDRD) equation 
recalibrated for Chinese people [18].
Examination of neurological symptoms and signs
Neurological symptoms and signs based on the neuropa-
thy symptom score (NSS) and the neuropathy disability 
scores (NDS) were evaluated [1], Neurological symptoms 
included burning, numbness, tingling, fatigue, cramp-
ing or aching, and neurological signs included vibration 
sense, pain, temperature sensation and ankle reflex. The 
symptoms and signs abnormalities assessed for DPN 
were in a glove/stoking distribution.
Nerve conduction velocity tests
An electromyography (EMG) machine (Keypoint®4; 
Tonsbakken 16-18, DK-2740 Skovlunde, Denmark) was 
utilized to assess sensory and motor nerve conduction 
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velocity (NCV) by the same neurologist. NCV studies 
of bilateral median, ulnar, tibial, common peroneal and 
superficial peroneal on each subject were conducted. 
Subjects stayed calm and relaxed, and the local skin tem-
peratures were kept at 32–33 °C throughout the examina-
tion. A decrease in NCV was set according to the NCV 
reference value for the Chinese population [19].
Diagnosis of DPN
DPN was diagnosed according to the modified Toronto 
Expert Consensus [3] as follows: (1) non-DPN, all neu-
rological symptoms/signs and NCV were normal; (2) 
clinical DPN, at least two abnormal results among neu-
rological symptoms/signs, or ankle reflex in accordance 
with a distal symmetrical polyneuropathy and normal 
NCV; (3) confirmed DPN, at least one abnormal nerve 
parameter (of NCV, amplitude, latency, and F-wave) 
in two or more nerves among the median, peroneal, 
and sural nerves, regardless of neurological signs and 
symptoms.
Statistical analysis
Data are presented as the mean  ±  standard devia-
tion or percent of individuals. Variance homogeneity 
was assessed by the Levene test. Differences in C-pep-
tide within the three groups were assessed by one-way 
ANOVA. The least significant difference and Dunnett 
tests were used to compare differences between groups 
with continuous variables, and a Chi square test was used 
to assess differences between categorical variables. Spear-
man’s correlation analysis was used to examine the cor-
relation of serum C-peptide concentrations with clinical 
variables. Multiple logistic regression analysis was per-
formed to evaluate the association of DPN and C-peptide 
quartiles after adjusting for other clinical and biochemi-
cal variables. Analysis was performed using SPSS 17.0 
(IBM Corporation, Somers, NY). A P value of <0.05 was 
considered to be statistically significant.
Results
The clinical characteristics of the patients in all three 
groups are summarized in Table 1. Compared to patients 
in the non-DPN group, those in the confirmed DPN 
groups had higher SBP (P  =  0.036), FPG (P  =  0.033), 
2  h-PG (P  =  0.012) and HbA1c (P  =  0.007) as well as 
lower HDL-C (P  =  0.018), NCV and nerve conduction 
amplitude (NCA) of median, titial and sural (all P < 0.05). 
However, no significant differences in age, sex, diabetes 
duration, smoking status, BMI, DBP, TC, TG, LDL-C, 
GA, Cr and eGFR were found among the three groups. 
The use of anti-diabetic drugs (e.g., metformin, sulfonylu-
reas and insulin) and anti-hypertension drugs [angioten-
sin-converting enzyme inhibitors (ACEI) or angiotensin 
receptor blocker (ARB)] were also not significantly differ-
ent among the three groups.
Fasting C-peptide, 2-hpostprandial C-peptide and 
ΔC-peptide concentrations in the non-DPN group 
(0.44  ±  0.15, 1.42  ±  0.92 and 1.00  ±  0.81  nmol/L, 
respectively) were significantly higher than in the 
clinical DPN group (0.35  ±  0.17  nmol/L, P  =  0.030; 
0.99 ± 0.75 nmol/L, P = 0.024 and 0.64 ± 0.68 nmol/L, 
P =  0.040, respectively) and the confirmed DPN group 
(0.24  ±  0.14  nmol/L, P  =  0.002; 0.41  ±  0.27  nmol/L, 
P  <  0.001 and 0.17  ±  0.22  nmol/L, P  <  0.001, respec-
tively). Additionally, both the 2-h postprandial C-peptide 
and ΔC-peptide concentrations were higher in the clini-
cal DPN group than in the confirmed DPN group (both 
P < 0.001; Fig. 1).
Fasting C-peptide, 2-h postprandial C-peptide and 
ΔC-peptide levels were all significantly correlated with 
diabetes duration (r1, −0.325; r2, −0.290 and r3, −0.234, 
respectively), FPG (r1, −0.271; r2, −0.572; and r3, −0.602, 
respectively), HbA1c (r1, −0.335; r2, −0.439 and r3, 
−0.419 respectively), GA (r1, −0.460; r2, −0.605 and r3, 
−0.522, respectively), median motor NCV (r1, 265; r2, 
0.326 and r3, 0.297, respectively), ulnar motor NCV (r1, 
286; r2, 0.401 and r3, 0.550, respectively) and sural sen-
sory NCV (r1, 277; r2, 0.248 and r3, 0.226, respectively).
Multiple logistic regression analyses were performed to 
evaluate the risk factors associated with DPN (including 
both clinical and confirmed DPN) (Table 2). After adjust-
ing for age, sex, diabetes duration, smoking status, BMI, 
SBP, ACEI/ARB use, FPG, HbA1c, TG and eGFR (model 
2), the association between serum C-peptide levels and 
DPN remained statistically significant (odds ratio [OR], 
0.329; 95% confidence interval [CI]), 0.107–0.903 for fast-
ing C-peptide, P = 0.028; OR, 0.712; 95% CI 0.556–0.913 
for 2-hpostprandial C-peptide, P = 0.007 and OR, 0.717; 
95% CI 0.548–0.939 for ΔC-peptide, P = 0.016].
Compared with the ΔC-peptide concentrations in 
quartile 1 (reference), patients in quartile 3 (OR 0.110; 
95% CI 0.026–0.466; P = 0.003) and quartile 4 (OR 0.012; 
95% CI 0.026–0.559; P = 0.007) had a lower risk of DPN 
(including both clinical and confirmed DPN) after adjust-
ing for age, sex, diabetes duration, smoking status, BMI, 
SBP, ACEI/ARB use, FPG, HbA1c, TG and eGFR. Trend 
test analysis showed a statistical difference in the preva-
lence of DPN among quartiles 2, 3 and 4, compared to 
quartile 1 (P < 0.001; Table 3). However, the same analysis 
of fasting C-peptide and 2-h postprandial C-peptide did 
not show a significant difference among the quartiles.
Discussion
This study suggested a close relationship between the 
serum C-peptide concentrations and DPN in commu-
nity-based Chinese type 2 diabetes patients. The decrease 
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in ΔC-peptide was strongly associated with the preva-
lence of DPN after adjusting for other variables.
Some studies showed that serum C-peptide concen-
tration had a protective effect on neuropathy. In a large 
clinic-based cohort of 471 type 1 diabetic patients, higher 
values conferred a protective effect (OR 0.59; 95% CI 
0.37–0.94) on diabetes microvascular complications 
including autonomic neuropathy, compared to C-peptide 
values in the lowest tertile (<0.06 nmol/L) [7]. However, 
the role of C-peptide concentrations for DPN in type 2 
patients was still controversial. A study in Korea showed 
that the risk for diabetic neuropathy was associated with 
the lower fasting serum C-peptide quartile and lower 
Table 1 Characteristic of subjects
Results expressed as mean (standard deviation) or percentage
DPN diabetic peripheral neuropathy, BMI body mass index, DBP diastolic blood pressure, SBP systolic blood pressure, FPG fasting plasma glucose, 2 h-PG 
2 h-postprandial glucose, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HbA1c 
glycosylated hemoglobin A1c, GA glycated albumin, Cr serum creatinine, eGFR estimated glomerular filtration rate, MNCV motor nerve conduction velocity, MNCA 
motor nerve conduction amplitude, SNCV sensory nerve conduction velocity, SNCA sensory nerve conduction amplitude, ACEI angiotensin-converting enzyme 
inhibitors, ARB, angiotensin receptor blocker, P1V3 non-DPN versus confirmed DPN, P1V2 non-DPN versus clinical DPN, P2V3 clinical DPN versus confirmed DPN
Non-DPN (128) P1V3 Clinically-DPN (35) P1V2 Comfirmed DPN (57) P2V3
Age (year) 62.3 ± 8.4 0.449 63.3 ± 10.7 0.527 64.5 ± 8.8 0.726
Sex (male %) 41% 0.568 58.40% 0.634 46% 0.62
Diabetes duration (year) 8.5 ± 7.2 0.084 9.7 ± 7.7 0.435 12.6 ± 6.9 0.228
Smoking 12 (9.4%) 0.736 4 (11.4%) 0.543 6 (10.5) % 0.612
BMI (kg/cm2) 25.1 ± 3.8 0.393 25.8 ± 4.7 0.421 26.9 ± 1.3 0.167
SBP (mmHg) 133 ± 16 0.036 135 ± 16 0.501 141 ± 13 0.056
DBP (mmHg) 78 ± 8 0.239 77 ± 11 0.431 83 ± 9 0.068
FPG (mmol/L) 8.40 ± 2.43 0.033 8.89 ± 2.33 0.523 9.37 ± 2.60 0.465
2 h-PG (mmol/L) 15.79 ± 4.81 0.012 16.47 ± 4.63 0.607 18.14 ± 4.81 0.263
TC (mmol/L) 5.30 ± 1.02 0.356 5.19 ± 1.06 0.737 5.10 ± 1.26 0.823
TG (mmol/L) 2.11 ± 1.17 0.742 2.38 ± 0.82 0.448 2.05 ± 1.12 0.383
HDL-C (mmol/L) 1.33 ± 0.45 0.018 1.18 ± 0.18 0.217 1.14 ± 0.22 0.788
LDL-C (mmol/L) 2.96 ± 0.77 0.906 3.02 ± 0.83 0.804 2.98 ± 1.09 0.878
HBA1c (%) 7.4 ± 1.4 0.007 7.6 ± 1.4 0.929 8.5 ± 1.9 0.229
GA (%) 18.7 ± 3.7 0.091 20.4 ± 5.2 0.417 22.8 ± 6.1 0.086
Cr (μmol/L) 61.54 ± 15.35 0.276 63.94 ± 17.11 0.63 67.6 ± 17.30 0.278
eGFR (mL/min/1.73 m2) 104.35 ± 31.32 0.857 106.34 ± 26.13 0.826 105.45 ± 30.86 0.93
Median MNCV 53.7 ± 3.1 <0.001 51.2 ± 5.7 0.033 46.5 ± 3.4 0.005
Median MNCA 8.9 ± 2.3 0.014 7.8 ± 2.8 0.398 6.9 ± 2.4 0.516
Median SNCV 51.8 ± 8.6 0.001 48.7 ± 8.8 0.086 41.9 ± 8.3 0.028
Median SNCA 21.4 ± 6.8 <0.001 17.0 ± 8.2 0.03 9.6 ± 5.4 <0.001
Tibial MNCV 44.5 ± 3.2 0.012 40.8 ± 5.89 0.007 35.8 ± 6.0 0.15
Tibial MNCA 8.7 ± 3.1 <0.001 8.2 ± 3.7 0.649 5.2 ± 3.5 0.02
Sural SNCV 50.3 ± 8.5 <0.001 47.5 ± 6.3 0.114 36.3 ± 3.9 0.002
Sural SNCA 13.2 ± 5.6 <0.001 10.4 ± 3.2 0.114 6.1 ± 3.1 <0.001
Insulin 16 (12.5%) 0.347 7 (20%) 0.576 13 (22.4%) 0.747
Sulfonylureas 32 (25.0%) 0.415 10 (28.6%) 0.589 21 (36.8%) 0.467
Metformin 46 (35.9%) 0.423 14 (40%) 0.71 25 (43.8%) 0.745
ACEI or ARB 33 (25.8%) 0.768 12 (34.3%) 0.896 19 (33.3%) 0.824
Fig. 1 Fasting C-peptide, 2-hpostprandial C-peptideand ΔC-peptide 
concentration in non-DPN group, clinical DPN group and confirmed 
DPN group. ΔC-peptide, 2 h-postprandial C-peptide minus fasting 
C-peptide
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ΔC-peptide quartile in type 2 diabetic patients after 
adjusting for multiple confounding factors [11]. A retro-
spective cohort study with a median follow-up of 14 years 
showed that the risks for incident neuropathy were nega-
tively associated with the highest C-peptide tertile (OR 
0.39; 95% CI 0.25–0.61) [12]. In a Chinese study that 
included hospitalized patients with type 2 diabetes, Zhao 
et al. [13] concluded that a higher level of area under the 
curve of C-peptide [AUC (C-pep)] was inversely associ-
ated with the prevalence of neuropathy. However, Sari 
et  al. [14] demonstrated that C-peptide did not corre-
late with sensorial neuropathy. Moreover, another study 
found that patients with parasympathetic neuropathy 
had elevated fasting plasma C-peptide (P  <  0.001) [15]. 
Our study focused on the relationship between C-pep-
tide concentration and DPN in community-based Chi-
nese patients, and the results suggested that the fasting 
C-peptide, 2-h postprandial C-peptide and ΔC-peptide 
concentrations were negatively associated with DPN 
after adjusting for multiple confounders.
In our study, DPN was associated with poor glycemic 
control as reflected by HbA1c, old age and longer dia-
betes duration. With increased diabetes duration, the 
islet function diminishes gradually, resulting in reduced 
C-peptide and insulin levels and the prevalence of DPN 
increases. Therefore, we conducted a different analysis 
to eliminate the effect of age and disease duration on the 
results. For example, under the circumstances of no obvi-
ous difference of age and diabetes duration among the 
three groups, the C-peptide differed significantly. Fur-
thermore, multiple logistic regression analysis showed 
a strong relationship between C-peptide and DPN even 
after adjustment for confounding factors including 
age, sex, diabetes duration, smoking status, BMI, SBP, 
ACEI/ARB use, FPG, HbA1c, TG and eGFR, indicat-
ing that C-peptide was independently associated with 
DPN. These results are consistent with other studies that 
included patients with lower HbA1c levels or shorter dis-
ease duration or younger age [10–12].
The beneficial effects of C-peptide on the prevention of 
diabetes complications in type 1 diabetes patients have 
been confirmed by various studies [8, 9]. In contrast, 
the role of C-peptide is not well-defined in type 2 diabe-
tes. Experimental studies in type 1 diabetes showed that 
C-peptide specifically bound to cell surfaces, acting via 
a G-protein-related receptor; it also led to autophospho-
rylation of the insulin receptor in the presence of insulin 
[20]. Moreover, C-peptide stimulated p38 MAP-kinase 
and PI-3 kinase activities, and diminished the activa-
tion of JNK phosphorylation with subsequent effects 
on Na+/K+-ATPase activity and nitric oxide (NO) [21, 
22]. C-peptide also ameliorated the altered expression 
of insulin-like growth factor-1, nerve growth factor and 
neurotrophin-3 and their respective receptors, which 
corrected neurofilament (NF) and tubulin mRNA, and 
protein expression, as well as normalized the aberrant 
phosphorylation of NFs [23]. C-peptide also stabilized 
the attachment of the α-Na+-channels at the nodal axo-
lemma, and furthermore, it prevented a breach of the 
paranodal ion-channel barrier. These results correlate 
with the corrected effects of C-peptide on nodal and 
paranodal structural integrity [24, 25]. In addition to the 
Table 2 Multiple regression analyses with the dependent variable of DPN and independent variable of C-peptide
Model1 adjusted for age, sex and diabetes duration
Model2 adjusted for age, sex and diabetes duration, smoking, systolic blood pressure, body mass index, angiotensin-converting enzyme inhibitors/angiotensin 
receptor blocker, fasting plasma glucose, glycosylated hemoglobin A1c, triglyceride, estimated glomerular filtration rate
Model1 Model2
Odds ratio (95% confidence interval) P Odds ratio (95% confidence interval) P
Fasting C-peptide 0.457 (0.234–0.892) 0.022 0.392 (0.170–0.903) 0.028
2 h-postprandial C-peptide 0.749 (0.621–0.904) 0.003 0.712 (0.556–0.913) 0.007
ΔC-peptide 0.733 (0.592–0.908) 0.004 0.717 (0.548–0.939) 0.016
Table 3 DPN risk in different ΔC-peptide quartiles
Multiple regression analyses and trend test analysis were used. The regression was adjusted for age, sex and diabetes duration, smoking, systolic blood pressure, body 
mass index, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker, fasting plasma glucose, glycosylated hemoglobin A1c, triglyceride, estimated 
glomerular filtration rate. ΔC-peptide, 2-hpostprandial C-peptide minus fasting C-peptide
Q1 Q2 Q3 Q4 P trend
(≤0.22 nmol/L) (0.23–0.59 nmol/L) (0.60–1.15 nmol/L) (>1.16 nmol/L)
Odds ratio (95% confidence interval) − 0.645 (0.191–2.175) 0.110 (0.026–0.466) 0.012 (0.026–0.559) <0.001
P − 0.479 0.003 0.007
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direct effect of the C-peptide on DPN, the residual beta 
cell function as represented by C-peptide concentrations 
also plays an important role. This highlighted the impor-
tance of some treatment strategies, such as avoiding 
drugs that overstimulate beta cells and initiating insulin 
therapy at an appropriate time to preserve endogenous 
beta cell activity in the progression of type 2 diabetes.
This study has some limitations that should be taken 
into account. First, due to its cross-sectional nature, we 
could not determine the causal relationship between the 
serum C-peptide levels and DPN. Thus, prospective stud-
ies are needed to confirm the protective effects of C-pep-
tide on DPN. Second, the relationship between C-peptide 
levels and severity of DPN was not analyzed. Third, the 
clinical confirmed DPN should be validated by small 
fibre examinations, such as corneal confocal microscopy. 
Finally, the relationship between C-peptide levels and 
other microvascular complications was not investigated. 
This relationship will be evaluated in further studies.
Conclusions
Serum C-peptide levels were significantly associated 
with DPN in community-based Chinese type 2 diabetic 
patients. In patients with low C-peptide levels, a high 
prevalence of DPN was observed. Decreased ΔC-peptide 
levels were strongly associated with the prevalence of 
DPN after adjusting for other confounding variables. 
Thus, C-peptide might play a potential protective effect 
on the occurrence of DPN in patients with type 2 dia-
betes. Large prospective studies should be conducted 
to define the causal correlation between C-peptide and 
DPN in type 2 diabetes mellitus.
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